Development
PROCEPT BioRobotics Corporation
PRCT
$62.91
-$2.14-3.29%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 83.29% | 72.50% | 98.33% | 71.90% | 134.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 83.29% | 72.50% | 98.33% | 71.90% | 134.53% |
| Cost of Revenue | 70.41% | 60.39% | 78.85% | 83.14% | 133.03% |
| Gross Profit | 99.09% | 84.48% | 117.17% | 62.39% | 136.40% |
| SG&A Expenses | 39.49% | 32.84% | 65.05% | 63.89% | 60.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.82% | 43.00% | 69.90% | 76.52% | 81.01% |
| Operating Income | -18.04% | -15.85% | -43.36% | -80.70% | -48.77% |
| Income Before Tax | 2.37% | -8.88% | -31.80% | -65.75% | -53.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.37% | -8.88% | -31.80% | -65.75% | -53.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.37% | -8.88% | -31.80% | -65.75% | -53.54% |
| EBIT | -18.04% | -15.85% | -43.36% | -80.70% | -48.77% |
| EBITDA | -15.84% | -14.73% | -45.61% | -84.56% | -51.71% |
| EPS Basic | 13.60% | -0.61% | -29.37% | -61.29% | -49.34% |
| Normalized Basic EPS | 2.30% | -0.60% | -29.35% | -61.29% | -32.04% |
| EPS Diluted | 13.60% | -0.61% | -29.37% | -61.29% | -49.34% |
| Normalized Diluted EPS | 2.30% | -0.60% | -29.35% | -61.29% | -32.04% |
| Average Basic Shares Outstanding | 13.00% | 8.22% | 1.89% | 2.76% | 2.82% |
| Average Diluted Shares Outstanding | 13.00% | 8.22% | 1.89% | 2.76% | 2.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |